Matthew D. Linden

3.4k total citations
83 papers, 2.3k citations indexed

About

Matthew D. Linden is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Matthew D. Linden has authored 83 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 37 papers in Cardiology and Cardiovascular Medicine and 17 papers in Internal Medicine. Recurrent topics in Matthew D. Linden's work include Platelet Disorders and Treatments (32 papers), Antiplatelet Therapy and Cardiovascular Diseases (28 papers) and Venous Thromboembolism Diagnosis and Management (17 papers). Matthew D. Linden is often cited by papers focused on Platelet Disorders and Treatments (32 papers), Antiplatelet Therapy and Cardiovascular Diseases (28 papers) and Venous Thromboembolism Diagnosis and Management (17 papers). Matthew D. Linden collaborates with scholars based in Australia, United States and United Kingdom. Matthew D. Linden's co-authors include Andrew L. Frelinger, Alan D. Michelson, Marsha L. Fox, Marc R. Barnard, Mark I. Furman, Denise E. Jackson, M.R. BARNARD, Youfu Li, Huyen Tran and Karin Przyklenk and has published in prestigious journals such as Circulation, Blood and Journal of the American College of Cardiology.

In The Last Decade

Matthew D. Linden

81 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Matthew D. Linden Australia 27 1.0k 763 409 359 283 83 2.3k
Marc R. Barnard United States 32 1.9k 1.9× 1.8k 2.3× 845 2.1× 652 1.8× 342 1.2× 59 4.4k
Dominique de Prost France 29 345 0.3× 742 1.0× 355 0.9× 202 0.6× 134 0.5× 71 3.1k
Milka Koupenova United States 20 426 0.4× 584 0.8× 259 0.6× 253 0.7× 93 0.3× 30 2.6k
J A Davies United Kingdom 23 639 0.6× 410 0.5× 372 0.9× 392 1.1× 140 0.5× 101 2.0k
Helge Stormorken Norway 27 726 0.7× 1.1k 1.4× 359 0.9× 339 0.9× 119 0.4× 134 2.7k
Andrew J. Catto United Kingdom 25 451 0.4× 859 1.1× 240 0.6× 248 0.7× 98 0.3× 50 2.2k
Vance G. Nielsen United States 33 459 0.5× 681 0.9× 601 1.5× 487 1.4× 107 0.4× 187 3.6k
L. Jörgensen Norway 26 613 0.6× 307 0.4× 504 1.2× 150 0.4× 84 0.3× 65 2.2k
Henk te Velthuis Netherlands 22 757 0.7× 339 0.4× 780 1.9× 91 0.3× 35 0.1× 35 2.3k
D. Ogston United Kingdom 25 366 0.4× 824 1.1× 278 0.7× 371 1.0× 76 0.3× 125 2.4k

Countries citing papers authored by Matthew D. Linden

Since Specialization
Citations

This map shows the geographic impact of Matthew D. Linden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew D. Linden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew D. Linden more than expected).

Fields of papers citing papers by Matthew D. Linden

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew D. Linden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew D. Linden. The network helps show where Matthew D. Linden may publish in the future.

Co-authorship network of co-authors of Matthew D. Linden

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew D. Linden. A scholar is included among the top collaborators of Matthew D. Linden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew D. Linden. Matthew D. Linden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilson, Lynne, Rebecca Howman, Carolyn Grove, et al.. (2024). Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis. Platelets. 35(1). 2304173–2304173. 2 indexed citations
2.
Haynes, Andrew, Matthew D. Linden, Kazunori Nosaka, et al.. (2017). Acute impact of conventional and eccentric cycling on platelet and vascular function in patients with chronic heart failure. Journal of Applied Physiology. 122(6). 1418–1424. 6 indexed citations
3.
Haynes, Andrew, Matthew D. Linden, Elisa Robey, et al.. (2017). Relationship between monocyte-platelet aggregation and endothelial function in middle-aged and elderly adults. Physiological Reports. 5(10). e13189–e13189. 10 indexed citations
4.
Piva, Terrence J., et al.. (2015). Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome. Seminars in Thrombosis and Hemostasis. 42(1). 55–62. 20 indexed citations
5.
Linden, Matthew D.. (2013). Platelet Physiology. Methods in molecular biology. 992. 13–30. 26 indexed citations
6.
Santhakumar, Abishek B., Matthew D. Linden, & Indu Singh. (2012). Taurine in Lower Concentration Attenuates Platelet Activity. Food and public health. 2(2). 58–64. 10 indexed citations
7.
Jackson, Denise E., et al.. (2012). Inhibition of platelet-mediated arterial thrombosis and platelet granule exocytosis by 3′,4′-dihydroxyflavonol and quercetin. Platelets. 24(8). 594–604. 26 indexed citations
8.
Linden, Matthew D., et al.. (2011). Teaching clinical trial design and management using an online virtual environment. UWA Profiles and Research Repository (University of Western Australia). 17. 107–113. 8 indexed citations
9.
Linden, Matthew D., et al.. (2011). Hemostatic Abnormalities and Relationships to Metabolic and Hormonal Status in Polycystic Ovarian Syndrome. Trends in Cardiovascular Medicine. 21(1). 6–14. 12 indexed citations
10.
Psaila, Bethan, James B. Bussel, Andrew L. Frelinger, et al.. (2011). Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. Journal of Thrombosis and Haemostasis. 9(11). 2302–2310. 87 indexed citations
11.
Frelinger, Andrew L., J.A. Jakubowski, M.R. BARNARD, et al.. (2007). The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Journal of Thrombosis and Haemostasis. 98(1). 192–200. 5 indexed citations
12.
Linden, Matthew D., M.I. Furman, Andrew L. Frelinger, et al.. (2007). Indices of platelet activation and the stability of coronary artery disease. Journal of Thrombosis and Haemostasis. 5(4). 761–765. 94 indexed citations
13.
Tarnow, Inge, Alan D. Michelson, Andrew L. Frelinger, et al.. (2007). Cystic fibrosis heterozygotes do not have increased platelet activation. Thrombosis Research. 121(2). 159–162. 3 indexed citations
14.
Jakubowski, Joseph A., Marc R. Barnard, Marsha L. Fox, et al.. (2007). The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thrombosis and Haemostasis. 98(7). 192–200. 38 indexed citations
15.
Frelinger, Andrew L., Mark I. Furman, Matthew D. Linden, et al.. (2006). Residual Arachidonic Acid–Induced Platelet Activation via an Adenosine Diphosphate–Dependent but Cyclooxygenase-1– and Cyclooxygenase-2–Independent Pathway. Circulation. 113(25). 2888–2896. 227 indexed citations
16.
Michelson, Alan D., Matthew D. Linden, M.I. Furman, et al.. (2006). Evidence that pre‐existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. Journal of Thrombosis and Haemostasis. 5(1). 75–81. 70 indexed citations
17.
Furman, M.I., Lori A. Krueger, Matthew D. Linden, et al.. (2005). GPIIb–IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis. 3(2). 312–320. 39 indexed citations
18.
Linden, Matthew D., Andrew L. Frelinger, Karin Przyklenk, Mark Furman, & Alan D. Michelson. (2005). Aspirin Resistance: Detection, Mechanisms and Clinical Implications. Current Cardiology Reviews. 1(3). 203–211. 3 indexed citations
19.
Furman, Mark I., Lori A. Krueger, Matthew D. Linden, et al.. (2004). Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. Journal of the American College of Cardiology. 43(12). 2319–2325. 104 indexed citations
20.
Boncinelli, S, M Marsili, P Lorenzi, et al.. (1993). Aspirin effect on early and late changes in acute lung injury in sheep. Intensive Care Medicine. 19(1). 13–21. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marc R. Barnard Breakdown of academic impact, for papers by Dominique de Prost Breakdown of academic impact, for papers by Milka Koupenova Breakdown of academic impact, for papers by J A Davies Breakdown of academic impact, for papers by Helge Stormorken Breakdown of academic impact, for papers by Andrew J. Catto Breakdown of academic impact, for papers by Vance G. Nielsen Breakdown of academic impact, for papers by L. Jörgensen Breakdown of academic impact, for papers by Henk te Velthuis Breakdown of academic impact, for papers by D. Ogston
Rankless by CCL
2026